323 results about "Doxorubicin" patented technology

The invention provides a preparation method and application of a high-efficiency encapsulated pH-responsive drug-loaded liposome. According to the method, two-phase fluid of a medicine aqueous solution and a lipid component organic solution in a micro-channel is accurately controlled, and the efficiently encapsulated liposome is prepared from bottom to top by utilizing a micro-mixing technology. Compared with a conventional passive drug loading method which is relatively low in encapsulation efficiency in preparation of hydrophilic drug nano-liposomes, the method provided by the invention can improve the encapsulation efficiency to be close to 95% under optimized prescription and process conditions. According to the invention, by adjusting the proportion of each component in the prescription and the preparation process, the release behavior of liposome drugs such as adriamycin and the like can be adjusted, and the drug release shows pH responsiveness. Through efficient encapsulation of adriamycin and the like and pH-responsive release of the liposome dosage form, the effects of efficacy enhancement and toxicity reduction are achieved in the anti-tumor treatment aspect.

The invention belongs to the technical field of immunoassay and biosensing, and provides a novel construction mode of a heterojunction dual-photoelectrode photoelectric sensing strategy and a preparation method of an in-situ heterojunction MIO photocathode. The invention relates to a preparation method of a heterojunction dual-photoelectrode type photoelectrochemical sensor based on multi-ball cascade DNA reaction amplification. Specifically, the design is composed of an In2O3 / CdS photoanode and an in-situ formed MIL-68 / In2O3 (MIO) photocathode. The heterojunction dual-photoelectrode sensing strategy effectively prolongs an electron-hole transmission path, enhances photo-generated charge separation, and realizes' super-open 'PEC signal output, thereby providing a steady baseline for signal conversion. Meanwhile, a multi-sphere cascade DNA reaction is combined to output a three-dimensional DNA net structure to provide a large number of sites for embedding of a PEC quenching probe doxorubicin-ferrocene carboxylic acid (DOX-FcCOOH), obvious PEC signal quenching is realized by utilizing the efficient competitive electron transfer capability of the three-dimensional DNA net structure, and finally, a signal conversion system with'opening-super opening-closing 'multistage response characteristics is constructed. The detection of the nucleic acid marker Pax-5a gene of the B cell acute lymphatic leukemia is realized by detecting target objects with different concentrations.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition for resisting doxorubicin cardiotoxicity and a preparation method, application and a preparation thereof. The invention provides a composition capable of resisting doxorubicin cardiotoxicity, the composition comprises diosmetin and loureirin B, the diosmetin and the loureirin B can be extracted through natural plants, the raw materials are low in cost and easy to obtain, and clinical popularization and application are facilitated. The cell experiment research finds that the combined administration of diosmetin and loureirin B can significantly improve the survival rate of adriamycin-damaged myocardial cells and significantly reduce the active oxygen level and positive cell rate, and verifies the synergistic interaction of diosmetin and loureirin B in resisting adriamycin cardiotoxicity.

The invention discloses a GelMA hydrogel composite material as well as a preparation method and application thereof, and belongs to the technical field of material preparation. A micro-needle-shaped GelMA hydrogel composite material (GelMA MNs) is prepared by grafting an anhydride functional group of methacrylic anhydride to a side chain amino group of gelatin, then doxorubicin and an aPD-L1 inhibitor are loaded into the GelMA MNs, a double-drug delivery system is established, and the prepared aPD-L1 / DoxatGelMA MNs can reduce skin injury to the maximum extent, and meanwhile, the aPD-L1 / DoxatGelMA MNs have a good application prospect. Recognition and killing of immune cells on melanoma cells are greatly started, immunogenic cell death (ICD) is promoted, and a new thought is provided for overcoming limitation of ICIs.

The invention relates to a multifunctional silica plastid integrating chemotherapy, immunotherapy and gas therapy, and relates to a preparation method of the multifunctional silica plastid and application of the multifunctional silica plastid in tumor diagnosis and treatment. The schematic diagram is as shown in the figure, the membrane components comprise conventional phospholipid and complex lipid, a chemotherapeutic drug doxorubicin (DOX) entrapped on a hydrophilic core and Fe3 (CO) 12 entrapped on a hydrophobic core, and the chemotherapeutic drug can be adjusted according to needs and is suitable for broad-spectrum tumor treatment. The drug-loaded silica plastid can generate part of carbon monoxide in a tumor high-concentration hydrogen peroxide (H2O2) environment and release internally-loaded chemotherapeutic drugs. Under the action of ultrasound (US), the multifunctional silicon plastid can realize fixed-point release of chemotherapeutic drugs DOX and carbon monoxide at a tumor site, the enrichment and uptake of the drugs at the tumor site are greatly improved, in addition, the system is combined with the alphaPD-L1 antibody, the immunosuppressive PD-L1 / PD-1 axis can be blocked, T cells are recruited to attack tumors, meanwhile, the immunosuppressive regulatory T cells (Tregs) are reduced, and the tumor treatment effect is improved. The tumor inhibition can be enhanced; the pulmonary metastasis can be obviously reduced.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The invention relates to the technical field of nano medicine, in particular to iron gambogic acid adriamycin nano particles, a preparation method and application. Gambogic acid, doxorubicin hydrochloride and an iron-containing compound are matched, carbonyl oxygen and hydroxyl in the gambogic acid and Fe < 3 + > form coordinate bonds, carbonyl and amino in the doxorubicin hydrochloride and a conjugated system in a benzene ring are combined with Fe < 3 + > through covalent bonds and pi-pi accumulation, a core-shell structure is formed, and the iron gambogic acid doxorubicin nano-particles are obtained. The particle size of the iron gambogic acid adriamycin nano-particles ranges from 2 nm to 10 nm. The iron gambogic acid adriamycin nano-particles have excellent multi-enzyme activity, autophagy amplification is effectively achieved, traditional chemotherapy drug resistance caused by autophagy is overcome, and the glioma chemotherapy effect is improved.

The invention belongs to the technical field of cancer drugs, and particularly relates to a pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from the pancreatin-responsive bioactive peptide and application of the pancreatin-responsive bioactive peptide. The trypsin response-based bioactive peptide 1-Pept (the sequence of the trypsin response-based bioactive peptide 1-Pept is naphthylacetic acid-phenylalanine-glycine-tyrosine-lysine-cysteine-aspartic acid) and an anti-cancer drug adriamycin can be jointly assembled into 1-Pept / Dox nanofiber hydrogel, and a cytoskeleton can be destroyed by combining nanofibers with Dox; a series of cascade events resulting in cellular dysfunction are initiated, including mitochondrial damage, activation of apoptosis-associated proteins, and nuclear damage, thereby cooperatively causing tumor ablation. Compared with the existing single anti-cancer drug adriamycin, the in-vivo and in-vitro anti-cancer effect of the compound is obviously superior to that of the adriamycin pure drug, and the compound has obvious advantages in the aspect of resisting colon cancer.

A nanoparticle generally comprising a targeting peptide-lipid conjugate, wherein a targeting peptide moiety of the targeting peptide-lipid conjugate comprises a GRP78 targeting peptide, a polyethylene glycol (PEG)-lipid conjugate, a drug-lipid conjugate comprising a prodrug moiety, wherein the drug-lipid conjugate comprises one or more of a mertansine (DM1) prodrug, a doxorubicin prodrug, and a bortezomib (BTZ) prodrug; and wherein the prodrug is linked to a lipid moiety of the drug-lipid conjugate via a phosphodiester bond or a boron ester bond; cholesterol comprising about 1 mol% to about 10 mol% of the nanoparticle; and distearoylphosphatidylcholine (DSPC).

The invention discloses application of combination of okannin and epirubicin in prevention and / or treatment of colon cancer, relates to the technical field of biological medicine, and is technically characterized in that a pharmaceutical composition comprises okannin and epirubicin, the preferable molar ratio is 15: 1 or 7.5: 1, and the pharmaceutical composition aims to reduce the dosage of epirubicin, reduce toxic and side effects and enhance the curative effect through a synergistic effect. The invention also comprises a method for detecting the influence of the pharmaceutical composition on colon cancer cell viability and apoptosis, and an animal model for evaluating the influence on the tumor growth of a colon cancer tumor-bearing mouse. The pharmaceutical composition disclosed by the invention can be used for remarkably inhibiting the proliferation of colon cancer cells and enhancing the apoptosis promoting effect of epirubicin, and shows a good anti-tumor effect and relatively low visceral organ toxicity in an animal model. The invention provides a safe and effective new treatment strategy for colon cancer patients.

The invention relates to a preparation method and application of dynamic borate bond hydrogel loaded with adriamycin and an alphaOX40 antibody, and belongs to the technical field of tumors. According to the invention, the dynamic borate bond hydrogel loaded with adriamycin and an alphaOX40 antibody is prepared, and the hydrogel is constructed on the basis of dynamic crosslinking of phenylboronic acid modified hyaluronic acid (HA-PBA) and tannic acid (TA) through a borate bond, and has excellent tissue adhesion and programmed drug release characteristics.

The invention relates to the technical field of biological medicines, and discloses application of AVEN as a target spot in preparation of a medicine for treating adriamycin cardiomyopathy. Wherein the AVEN is taken as the target spot, the AVEN is overexpressed by targeting cardiac myocardial cells, and further, the overexpressed AVEN by targeting cardiac myocardial cells comprises the step of improving the expression of the AVEN gene in the cardiac myocardial cells by adopting a substance capable of activating or up-regulating the expression of the AVEN in a targeting manner. It is found for the first time that specific overexpression of AVEN in myocardial cells can inhibit ferroptosis of myocardial cells, relieve myocardial fibrosis and myocardial atrophy, significantly improve adriamycin-induced cardiac dysfunction, and improve life quality and long-term prognosis of patients.

The invention discloses an application of hydroxygenkwanin (HGK) in preparation of a drug for preventing and treating cardiotoxicity induced by antitumor drugs. The method comprises the following steps: inducing doxorubicin (DOX), establishing a myocardial cell H9C2 injury model, and determining the DOX-induced myocardial cell injury minimum concentration; after 20 [mu] M of HGK is added into a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, and compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and ejection fraction (EF%) of mice in the doxorubicin and hydroxygenkwanin group are remarkably increased, the myocardial fiber structure is improved, the cytoplasm vacuolation is reduced, the levels of serum cTnT, CK-MB and BNP are reduced, and the ROS level of heart tissue is reduced. Therefore, the hydroxygenkwanin can obviously reduce the cardiotoxicity induced by the DOX.

The invention provides a drug delivery system combined with targeted nasopharyngeal carcinoma treatment and a preparation method and application thereof, and belongs to the technical field of biomedicine.The drug delivery system is characterized in that a liposome is modified by a nucleic acid aptamer S3 specifically targeting nasopharyngeal carcinoma cells, and then an anti-cancer drug adriamycin is entrapped for targeted killing of NPC cells and tissues; besides, NK cells modified by nucleic acid aptamers S3 and PD-L1 are prepared for targeted infiltration of NPC tissues, the NK cells modified by the nucleic acid aptamers S3 and PD-L1 are combined with anti-PD-L1 antibodies to induce'antibody-dependent cytotoxic effect ', and finally, a chemotherapeutic drug targeted delivery system and immunotherapy are organically combined to form a multi-mode therapeutic scheme. And while multi-angle and multi-layer striking is carried out on tumors, the toxic and side effects on normal cells and tissues can be reduced, and the treatment effect on nasopharyngeal carcinoma patients is remarkably improved.

The invention relates to a multifunctional manganese-based hybrid nano-platform based on NK cell membrane modification and a preparation method and application thereof, by selecting a highly branched dendritic polymer PSeSeS modified by a diselenide bond as a carrier and partially modifying mPEG and phenylboronic acid, water solubility and stability are improved, and the material is endowed with specific reactivity in a tumor microenvironment. Furthermore, potassium permanganate is reduced by using the tail end of PSeS and a tertiary amine group to generate MnO nano-particles, so that the low-oxygen environment of tumors is relieved, the photothermal therapy is enhanced, and meanwhile, active oxygen can be generated. Then doxorubicin and cGAMP are loaded, chemotherapy and immunotherapy are combined, and the tumor recognition and removal capacity of an immune system is improved; nK cell membrane modification is further adopted, so that the targeting property and the in-vivo stability are improved. The nano platform overcomes the defects of poor tumor microenvironment responsiveness, weak targeting, inaccurate drug release, single treatment mode and the like in the prior art, and can significantly improve the effect and safety of liver cancer treatment.

The invention provides a nanoparticle for treatment of polydopamine loaded resveratrol sensibilization adriamycin and a preparation method of the nanoparticle for treatment of polydopamine loaded resveratrol sensibilization adriamycin. The nanoparticle takes polydopamine as an inner core, adriamycin and resveratrol are loaded together, and the targeting property of the nanoparticle is enhanced through folic acid modification. The resveratrol remarkably enhances the cytotoxicity of the adriamycin by down-regulating HSP27, and generates a synergistic effect with the adriamycin, so that the sensitivity of breast cancer cells to the adriamycin is effectively improved, and the treatment effect is enhanced. The nanoparticles provide a new strategy for breast cancer treatment, especially for a treatment path of heat shock protein HSP27 regulation, and show a wide application prospect.

The invention discloses application of terpinenol compounds in preparation of medicines for treating heart diseases, in particular to preparation of medicines for resisting heart failure. After doxorubicin-induced chronic heart failure rat models are administered, the terpinenol compound can obviously increase the maximum rising rate and the maximum decreasing rate of left ventricular internal pressure in the doxorubicin-induced chronic heart failure rat models, increase the rat heart ejection fraction in the chronic heart failure rat models, relieve the heart hemodynamics of the chronic heart failure rats to a certain extent, and improve the curative effect of the doxorubicin-induced chronic heart failure rats. Experimental evidence is provided for clinical application of the terpinenol compound to treatment of heart failure, and the terpinenol compound has good application and development prospects.

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The application discloses a kind of 2-substituted benzylhydrazine-4-indole pyrimidine-5-carbonitrile derivatives and preparation method and application thereof.The derivative has general formula (I) structure: wherein R is hydroxyl or C1-C4 alkoxy, n=1~3.Preferred compound is 2-hydroxy, 4-hydroxy-3-methoxy, 2,3-dihydroxy or 2,4-dihydroxy substituted benzylhydrazine derivative.The application also provides key intermediate 2-hydrazine-4-(1H-indole-3-carbonyl) pyrimidine-5-carbonitrile and preparation method thereof.In vitro antitumor activity shows that the derivative has excellent inhibitory activity on human gastric cancer cell MGC-803, and the inhibition rate is up to 96.3% at 10 μmol / L, which is better than positive control doxorubicin.In vivo combination test shows synergistic effect with 5-fluorouracil or anti-PD-1 antibody.The compound of the application has mild synthesis route, high yield, various preparation forms, good safety, and can be applied in the preparation of anti-gastric cancer drugs.

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

The present invention relates to an isoindolinone derivative, a preparation method, a pharmaceutical composition and an application. The derivative is a compound of formula I or a pharmaceutically acceptable salt of the compound of formula I, wherein Ra is one of a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C6 alkyl; Rb and Rc are each one of a substituted or unsubstituted C1-C6 alkyl. Compared with the prior art, the isoindolinone derivative in the present invention has a novel structure, has significant anti-cancer cell proliferation activity, and the activities of multiple compounds are superior to those of doxorubicin.

The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.

The invention provides a DNA (Deoxyribose Nucleic Acid) nano-structure carrier. The DNA nano-structure carrier provided by the invention has an EGFR (epidermal growth factor receptor) aptamer structure and is used for loading a connecting sequence of siRNA; moreover, after the siRNA is loaded, the DNA nano-structure carrier can further load a chemotherapeutic drug such as adriamycin, so that a DNA nano-drug based on the DNA nano-structure carrier is obtained. Through the target gene expression knock-down effect of siME3, the cytotoxicity of adriamycin and the targeting property of the EGFR aptamer structure, the DNA nano-drug provided by the invention can effectively inhibit pancreatic cancer, especially the growth of ME2 deletion type pancreatic cancer cells.

The present application relates to the technical field of biological medicine, and discloses inhalable aptamer modified molybdenum disulfide nanoflower compound and application thereof.The compound comprises a molybdenum disulfide nanoflower core, a dendritic polylysine modification layer attached to the surface of the molybdenum disulfide nanoflower, doxorubicin loaded on the molybdenum disulfide nanoflower and / or the dendritic polylysine modification layer, and AS1411 aptamer combined on the outer surface of the dendritic polylysine modification layer by electrostatic assembly.The compound can be delivered to a lung lesion by atomization inhalation or aerosol inhalation, and undergoes responsive structural change under the action of hydrogen peroxide in a tumor microenvironment, generates active oxygen, and promotes the release of doxorubicin, so as to realize the synergistic antitumor effect of chemotherapy and chemical dynamic therapy.The compound has good colloidal stability, drug loading capacity, active targeting ability and lung local delivery potential, and can be used for preparing inhalation preparations or local administration preparations for treating lung cancer.

We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

This invention discloses a hydrogel for tumor treatment based on improving the tumor microenvironment to trigger gas therapy combined with chemotherapy, belonging to the field of biomedical technology. The hydrogel drug delivery system utilizes lipopolysaccharide (LPS) to induce local inflammatory stimulation, thereby altering the tumor microenvironment of breast cancer and promoting nitric oxide (NO) production. The NO donor arginine (L-Arg) and the chemotherapy drug doxorubicin (DOX) are transported using sodium alginate (ALG), achieving combined gas therapy and chemotherapy to inhibit breast tumor growth. The drug delivery system of this invention not only enhances the effect of chemotherapy but also simultaneously achieves precise drug delivery and reduces drug dosage. The preparation method of the drug delivery system of this invention is simple, safe, and without toxic side effects, showing promising application prospects in tumor treatment and possessing significant clinical value.

Disclosed are an anthracycline compound, a preparation method therefor, an intermediate, and a use thereof. The present invention provides an anthracycline compound as shown in formula I or a pharmaceutically acceptable salt thereof. The anthracycline compound provided by the present invention has antitumor activity comparable to existing anthracycline drugs (such as nemorubicin) or greater than that of existing anthracycline drugs doxorubicin and daunorubicin, and does not form an oxazole ring structure during metabolism, thereby improving the clinical safety of such drugs.

A combination therapy for the treatment of cancer, particularly soft tissue sarcoma, is described, which includes low doses of lurbinectedin and doxorubicin.

The invention discloses a manganese urate material, a gel preparation and application thereof, and relates to the technical field of gel preparations. The manganese urate material provided by the invention can enhance anti-tumor immune response, and has good application prospects of adjuvants, vaccines and medicines. Besides, the invention also provides a gel preparation, the preparation is a multifunctional temperature-sensitive hydrogel preparation taking poloxamer as a matrix, and the preparation is combined with artesunate, adriamycin, uric acid and manganese to realize efficient treatment of various tumors such as breast cancer and inhibit postoperative recurrence of the tumors.